论文部分内容阅读
目的:探讨细胞因子诱导的杀伤细胞在难治性淋巴瘤患者中的应用及临床效果。方法:8例难治性淋巴瘤患者,通过血细胞分离机采集外周血单个核细胞,培养和扩增细胞因子诱导的杀伤细胞后回输至难治性淋巴瘤患者体内,评价其疗效。结果:细胞因子诱导的杀伤细胞治疗后患者自觉症状改善,影像学复查显示1例多发侵犯肿块基本消失,7例肿块均有不同程度缩小,T细胞亚群水平在回输后均有明显升高。结论:细胞因子诱导的杀伤细胞治疗难治性淋巴瘤患者可改善生活质量,不良反应小,有较好的临床效果,为难治性淋巴瘤提供了一种新的治疗方案。
Objective: To investigate the application and clinical effect of cytokine-induced killer cells in patients with refractory lymphoma. Methods: Eight patients with refractory lymphoma were collected from peripheral blood mononuclear cells by hemacytometer. After cytokine-induced killer cells were cultured and expanded, they were transfused into patients with refractory lymphomas and their therapeutic effects were evaluated. Results: After treatment with cytokine-induced killer cells, the patients’ symptoms improved. Radiographic examination showed that one case of multiple invasive lesions basically disappeared. All the seven cases were reduced to varying degrees. The T-cell subsets were significantly increased after reinfusion . Conclusion: Cytokine-induced killer cells in patients with refractory lymphoma can improve the quality of life, with small adverse reactions, have a good clinical effect, providing a new treatment for refractory lymphoma.